About us

RetiPharma is developing products for treatment of degenerative eye disorders in parallel with building a unique translational in vivo platform. The company is founded on neuroprotective research conducted by scientist at the University of Copenhagen and the University Hospital, Rigshospitalet.

RetiPharma is supported by a strong scientific and clinical team led by Associated Professor David Woldbye, MD, and Chief Physician, Kristian Klemp, MD, specialised in retinal eye surgery.

RetiPharma is supported by The Novo Nordisk Fondation’s BioInnovation Institute with funding for preparing a candidate drug for a clinical proof-of-concept study as well as source additional compounds using RetiPharma’s translational platform.